| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | FG-3246 (first-in-class antibody-drug conjugate) metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
phase 2 data readout example | FG-3246 (first-in-class antibody-drug conjugate) metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
phase 2 data readout example | FG-3246 (first-in-class antibody-drug conjugate) metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | — | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
FibroGen, Inc$9.71
+0.48 (+5.2%)
Market Cap
39.28 M
EPS
40.44
P/E Ratio
0.24 $
Value Trade
324.53 K
11.1 %
Week
14.1 %
1 Month
-14.22 %
3 Month
30.34 %
6 Month
-99 %
5 Year
-98.31 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
34.23 K
52 Week Range
4.85 - 21.94
% held by Insiders
2.4 %
% held by Institutions
25.59 %
Enterprise Value
-23.14 M
Total Shares
4.04 M
Short %
2.95 %
Float Shares
3.90 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
roxadustat | anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) | Phase 3 | 2025-08-07 | |||
roxadustat | anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) | Phase 3 | 2025-08-07 | |||
roxadustat | anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) | Phase 3 | 2025-08-07 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
FGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FGEN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
FGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest FibroGen, Inc (FGEN) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How FGEN ranks across every disease it competes in No competitive intelligence available for FGEN.